Clinical Trial Update: Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating adalimumab in psoriasis patients with suboptimal response to systemic therapy or phototherapy; the study is completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2010-05-28